[Clinical trial of a new topical anti-histamine agent histimet in the treatment of seasonal allergic rhinoconjunctivitis]. / Opyt primeneniia novogo topicheskogo antigistaminnogo preparata gistimet v lechenii sezonnogo allergicheskogo rinokon''iunktivita.

21 patients with seasonal allergic rhinoconjunctivitis (SAC) entered the trial of a new topical antihistamine drug histimet (levocabastine). The drug is available as a nasal spray and eye drops. The relief of the main symptoms of SAC occurred 15-20 min after histimet introduction into the nose or eye. The effect of a single procedure lasted for 12 hours. Regression of SAC basic symptoms continued for 7 days after using histimet. A significant improvement of life quality was observed. Good effect achieved in 90% of the patients characterizes histimet as an effective new modality in SAC management.

[Analysis of immunocompetent cell subpopulations in chronic bronchitis patients during the use of different immunomodulating preparations]. / Analiz subpopuliatsii immunokompetentnykh kletok u bol'nykh khronicheskim bronkhitom na fone primeneniia razlichnykh immunomoduliruiushchikh preparatov.

Twenty-seven patients with chronic obstructive bronchitis and 47 patients with chronic non-obstructive bronchitis were subjected to subpopulation analysis of peripheral blood immunocompetent cells. Statistically significant changes in the content of T mu and T gamma cells, killer and suppressor activity of lymphocytes were discovered in patients with chronic bronchitis. One of the immunological differences between chronic obstructive and chronic non-obstructive bronchitis lies in the activity of Con A-induced suppressors, which is appreciably lowered in patients with chronic obstructive bronchitis.